Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Single-arm Study of nEoadjuvant Zanzalintinib (XL092) Plus nivoLumab in Patients With lOcally Advanced and/or inopeRable clEar Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis (EXPLORE-RCC)

NCT06794229 is registered in ClinicalTrials.gov with Qian Qin as lead sponsor.

NCT NCT06794229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06794229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Single-arm Study of nEoadjuvant Zanzalintinib (XL092) Plus nivoLumab in Patients With lOcally Advanced and/or inopeRable clEar Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis (EXPLORE-RCC)
Lead sponsor
Qian Qin
Phase
Phase 2
Overall status
Recruiting
Start date
October 30, 2025
Completion date
June 6, 2029
Enrollment
69 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced renal cell carcinoma